Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2281 · 8 trials · 9 indications
PFS was defined as the time from randomisation to the earlier date of radiological progression (per RECIST criteria) or death by any cause in the absence of objective progression. \[Full analysis set (FAS)\]
PFS was defined as the time to progression from the date of randomisation until the date of radiological assessment of progression per RECIST criteria or death (by any cause in the absence of progression)
Percentage of participants with confirmed best RECIST response of complete response (CR) or partial response (PR). Patients with a best RECIST response of CR or PR had to have a confirmed response at least 28 days later.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD2281 |
| 2 | PLACEBO_COMPARATOR | matching placebo |
| 3 | EXPERIMENTAL | AZD2281 Oral 400 mg BID |
| 4 | EXPERIMENTAL | Known BRCA mutation positive ovarian cancer: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally AZD2281, PARP inhibitor Olaparib tablets, oral |
| Treatment A | EXPERIMENTAL | 300mg bid (twice daily) tablet dose |
| Treatment B | EXPERIMENTAL | 400 mg twice daily (bid) capsule dose |
| Treatment C | EXPERIMENTAL | 400mg bid (twice daily) tablet dose |
| Name | Type | Description |
|---|---|---|
| AZD2281 | DRUG | Tablets Oral BID |
| matching placebo | DRUG | matching placebo bid |
| Liposomal Doxorubicin | DRUG | 50mg/m2 Monthly Intravenous |
| Cisplatin | DRUG | IV every 3 weeks |
| Paclitaxel | DRUG | Intravenous infusion over 1 hour |
| Bevacizumab | DRUG | IV administration10 mg/kg every 14 days |
Inclusion Criteria: * Female patients with histologically diagnosed serous ovarian cancer or recurrent serous ovarian cancer. * Patients must have completed at least 2 previous courses of platinum containing therapy; the patient must have been platinum sensitive to the penultimate chemo regimen. * ...
Top 20 of 59 competitors
AZD2281 is an investigational small molecule being studied in oncology for ovarian carcinoma, solid tumors, breast cancer, advanced solid tumors, ovarian neoplasms, and neoplasm metastasis. It is in clinical development and has not been approved by regulatory authorities.
AZD2281 is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in various cancer indications.
AZD2281 is in Phase 1 and Phase 2 clinical trials. It is an investigational drug, meaning it has not yet received regulatory approval and is still undergoing clinical evaluation for safety and effectiveness.
AZD2281 has been studied in several trials, including NCT00633269, a Phase 1 study in patients with solid metastatic tumors; NCT00679783, a Phase 2 study in ovarian cancer and breast cancer; NCT00707707, a Phase 1/2 study in metastatic triple negative breast cancer; and NCT00777582, a Phase 1 bioavailability study in solid tumors.
AZD2281 is a poly (ADP-ribose) polymerase (PARP) inhibitor. It works by blocking PARP enzymes, which are involved in DNA repair, potentially leading to cancer cell death, particularly in tumors with BRCA mutations.